loading
Outlook Therapeutics Inc stock is traded at $2.04, with a volume of 535.55K. It is up +2.00% in the last 24 hours and up +13.33% over the past month. Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$2.00
Open:
$2.02
24h Volume:
535.55K
Relative Volume:
0.73
Market Cap:
$68.48M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.51
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
-6.42%
1M Performance:
+13.33%
6M Performance:
+2.51%
1Y Performance:
-75.54%
1-Day Range:
Value
$1.98
$2.05
1-Week Range:
Value
$1.98
$2.19
52-Week Range:
Value
$0.87
$8.70

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name
Name
Outlook Therapeutics Inc
Name
Phone
(609) 619-3990
Name
Address
111 S. WOOD AVENUE, ISELIN, NJ
Name
Employee
23
Name
Twitter
Name
Next Earnings Date
2024-08-14
Name
Latest SEC Filings
Name
OTLK's Discussions on Twitter

Compare OTLK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
OTLK
Outlook Therapeutics Inc
2.04 85.71M 0 -51.50M -47.10M -4.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-02-24 Downgrade Chardan Capital Markets Buy → Neutral
Mar-27-24 Upgrade BTIG Research Neutral → Buy
Feb-15-24 Upgrade Chardan Capital Markets Neutral → Buy
Jan-25-24 Upgrade Guggenheim Neutral → Buy
Dec-27-23 Upgrade CapitalOne Equal Weight → Overweight
Aug-31-23 Downgrade Chardan Capital Markets Buy → Neutral
Aug-31-23 Downgrade H.C. Wainwright Buy → Neutral
Aug-30-23 Downgrade BTIG Research Buy → Neutral
Aug-30-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Aug-30-23 Downgrade CapitalOne Overweight → Equal Weight
Aug-30-23 Downgrade Guggenheim Buy → Neutral
Jul-13-23 Initiated CapitalOne Overweight
Apr-03-23 Initiated Guggenheim Buy
Feb-06-23 Initiated Cantor Fitzgerald Overweight
Oct-31-22 Initiated BTIG Research Buy
Sep-13-22 Initiated Chardan Capital Markets Buy
Sep-11-19 Initiated Ladenburg Thalmann Buy
May-16-19 Initiated Oppenheimer Outperform
Apr-22-19 Initiated Ascendiant Capital Markets Buy
View All

Outlook Therapeutics Inc Stock (OTLK) Latest News

pulisher
11:15 AM

What catalysts could drive Outlook Therapeutics Inc. stock higher in 2025Dynamic growth stocks - jammulinksnews.com

11:15 AM
pulisher
07:10 AM

Top Risks to Consider Before Buying Outlook Therapeutics Inc. StockSafe High Return Entry Points - Newser

07:10 AM
pulisher
04:59 AM

Outlook Therapeutics Inc. Stock Support and Resistance Levels You Should KnowBig Return Stock Tips - Newser

04:59 AM
pulisher
Jul 26, 2025

Why Outlook Therapeutics Inc. stock attracts strong analyst attentionSmall Risk Large Return Trades - Newser

Jul 26, 2025
pulisher
Jul 25, 2025

Outlook Therapeutics, Inc. shares fall 2.45% after-hours amid mixed market sentiment. - AInvest

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Outlook Therapeutics Inc. stockPowerful growth strategies - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase - GlobeNewswire

Jul 24, 2025
pulisher
Jul 24, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Jul 24, 2025
pulisher
Jul 24, 2025

Outlook Therapeutics Inc. Stock Analysis and ForecastFree Investment Timing Strategies - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Outlook Therapeutics to Present at the 8th Annual Ophthalmology - GuruFocus

Jul 24, 2025
pulisher
Jul 24, 2025

Outlook Therapeutics Showcases Breakthrough Retina Treatment Innovation at Elite Ophthalmology Summit - Stock Titan

Jul 24, 2025
pulisher
Jul 23, 2025

What drives Outlook Therapeutics Inc. stock priceFree Risk Assessment Services - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

Outlook Therapeutics Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times

Jul 22, 2025
pulisher
Jul 22, 2025

Exclusive: Outlook Therapeutics' New CEO Bob Jahr Reveals Growth Strategy for Retina Disease Treatment - Stock Titan

Jul 22, 2025
pulisher
Jul 20, 2025

Is Outlook Therapeutics Inc. a good long term investmentOutstanding growth strategies - Autocar Professional

Jul 20, 2025
pulisher
Jul 18, 2025

Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners are retail investors who got richer after stock soared 14% last week - simplywall.st

Jul 18, 2025
pulisher
Jul 17, 2025

Outlook Therapeutics(OTLK) Drops 4.15% Amid Biotech Volatility - AInvest

Jul 17, 2025
pulisher
Jul 15, 2025

How Outlook Therapeutics Inc. stock performs during market volatilityCapital Doubling Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Outlook Therapeutics Inc. stock price move sharplyFree Expert-Led Investment Training - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Outlook Therapeutics (OTLK) Soars 12.08% on Clinical Trial Success - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Oncobiologics, Inc. (NASDAQ:OTLK) Receives $9.60 Consensus PT from Analysts - Defense World

Jul 14, 2025
pulisher
Jul 09, 2025

Outlook Therapeutics shares rise 3.12% intraday after recent Federal Circuit's Disclosure-Level Test In In Re Riggs. - AInvest

Jul 09, 2025
pulisher
Jul 08, 2025

What caused OTLK's net profit surge in Q3 2024? - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Jul 08, 2025
pulisher
Jul 04, 2025

Outlook Therapeutics announces CEO appointment - MSN

Jul 04, 2025
pulisher
Jul 03, 2025

INVESTOR ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 02, 2025

SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jul 02, 2025
pulisher
Jul 02, 2025

Outlook Therapeutics Appoints New CEO Robert Charles Jahr - The Globe and Mail

Jul 02, 2025
pulisher
Jul 01, 2025

Outlook Therapeutics Appoints Bob Jahr as CEO - citybiz

Jul 01, 2025
pulisher
Jul 01, 2025

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer | OTLK Stock News - GuruFocus

Jul 01, 2025
pulisher
Jul 01, 2025

Outlook Therapeutics Appoints Bob Jahr as Chief Executive Officer | OTLK Stock News - Quiver Quantitative

Jul 01, 2025

Outlook Therapeutics Inc Stock (OTLK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):